Home » Stocks » AIMT

Aimmune Therapeutics, Inc. (AIMT)

Oct 13, 2020 - AIMT was delisted after being acquired by NSRGY
Stock Price: $34.49 USD 0.00 (0.00%)
Updated Oct 13, 2020 4:00 PM EDT
Market Cap 2.26B
Revenue (ttm) 575,000
Net Income (ttm) -287.03M
Shares Out 65.18M
EPS (ttm) -4.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Oct 13, 2020
Last Price $34.49
Previous Close $34.49
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 34.48 - 34.56
Day's Volume 0
52-Week Range 10.09 - 37.00

News

Hide News
GlobeNewsWire - 4 months ago

Vevey, October 14, 2020

Other stocks mentioned: NSRGY
Reuters - 4 months ago

Aimmune Therapeutics Inc shareholders have backed Nestle's $2 billion offer to gain full ownership of the first U.S.-approved peanut allergy treatment, which has struggled with a slow launch d...

Other stocks mentioned: NSRGY
GlobeNewsWire - 4 months ago

Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.

Other stocks mentioned: NSRGY
InvestorPlace - 4 months ago

Nestle picked my Best Stocks pick up for a steal, but I believe the decade of biotechnology is just now getting started. The post Best Stocks for 2020: Aimmune Therapeutics Gets Picked Up for ...

Seeking Alpha - 5 months ago

AIMT's stock fell precipitously amid the COVID-19 pandemic, despite receiving FDA approval for its Palforzia treatment (the first FDA approved treatment for peanut allergies).

PRNewsWire - 5 months ago

NEW YORK, Sept. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in N...

GlobeNewsWire - 5 months ago

Vevey, September 14, 2020

Other stocks mentioned: NSRGY
PRNewsWire - 5 months ago

NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Aimmune Therapeutics, Inc.

The Motley Fool - 5 months ago

Nestle is buying the small-cap biotech, and it's paying a high premium.

PRNewsWire - 5 months ago

PHILADELPHIA, Sept. 5, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Aimmune Therapeutics, Inc.

The Motley Fool - 5 months ago

These drugmakers are in the sweet spot to provide market-beating returns.

Other stocks mentioned: NSRGY
Business Wire - 5 months ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

CNBC Television - 6 months ago

Nestle CEO on the company's Aimmune Therapeutics acquisition

Mark Schneider, Nestle CEO, joins 'Closing Bell' to discuss the company's acquisition of peanut allergy treatment maker Aimmune and on consumer trends he's seeing.

Other stocks mentioned: NSRGY
Newsfile Corp - 6 months ago

Wilmington, Delaware--(Newsfile Corp. - September 1, 2020) - Rigrodsky & Long, P.A.

Zacks Investment Research - 6 months ago

Aimmune (AIMT) reaches an agreement with Nestle, S.A wherein the latter will acquire the company in an all-cash transaction worth $2.6 billion. Shares surge.

Other stocks mentioned: NSRGY
GuruFocus - 6 months ago

Swiss giant adds third drug to its portfolio this year

Other stocks mentioned: NSRGY
Yahoo Finance - 6 months ago

Aimmune Therapeutics confirms $2B Nestle acquisition

On Monday, Aimmune Therapeutics announced that it had agreed to Nestle’s $2 billion dollar acquisition.

Other stocks mentioned: NSRGY
PRNewsWire - 6 months ago

NEW YORK, Aug. 31, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Aimmune Therapeutics, Inc. ("...

The Motley Fool - 6 months ago

It was a mixed day for the markets.

Other stocks mentioned: NSRGY, UTZ
InvestorPlace - 6 months ago

Aimmune Therapeutics' news of its agreement with Nestle regarding its food allergy treatment has AIMT stock soaring way higher on Monday.

Other stocks mentioned: NSRGY
24/7 Wall Street - 6 months ago

Aimmune Therapeutics Inc. (NASDAQ: AIMT) shares more than doubled to start out the week after reports surfaced that the company would be acquired by Nestle Health Sciences, a subsidiary of the...

Other stocks mentioned: NSRGY
CNN Business - 6 months ago

Nestlé is buying the maker of a peanut allergy drug for children for $2.6 billion as it deepens its focus into health care and nutrition.

Other stocks mentioned: NSRGY
Business Wire - 6 months ago

NEW YORK--(BUSINESS WIRE)--Rowley Law PLLC is investigating potential securities law violations by Aimmune Therapeutics, Inc. (NASDAQ: AIMT) and its board of directors concerning the proposed ...

Fast Company - 6 months ago

Nestlé is shelling out an estimated $2.6 billion to buy a biopharmaceutical company best known for its peanut-allergy treatment. Nestlé is shelling out an estimated $2.6 billion to buy a biop...

Other stocks mentioned: NSRGY
Newsfile Corp - 6 months ago

New York, New York--(Newsfile Corp. - August 31, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orde...

Other stocks mentioned: NSRGY
Investors Business Daily - 6 months ago

Swiss food giant Nestle early Monday announced an agreement to buy Aimmune Therapeutics, the maker of the only approved drug to treat peanut allergies, for $2.6 billion. AIMT stock soared.

Other stocks mentioned: NSRGY
The Motley Fool - 6 months ago

Nestle is gobbling up the peanut allergy drugmaker Aimmune Therapeutics for a cool $2.6 billion.

Other stocks mentioned: NSRGY
24/7 Wall Street - 6 months ago

The world’s largest consumer products company, Nestlé S.A., has agreed to acquire Aimmune Therapeutics Inc.

Other stocks mentioned: NSRGY
Business Wire - 6 months ago

TAIPEI, Taiwan--(BUSINESS WIRE)--Oak Stone Limited have commented on Nestle after it announced its definitive agreement to purchase biopharma company Aimmune for $2.6 billion.

Other stocks mentioned: NSRGY
Invezz - 6 months ago

Nestle (SWX: NESN) on Monday expressed plans of buying Aimmune Therapeutics for £1.95 billion. The Brisbane-based biopharmaceutical company is largely known for its peanut allergy treatment.

Other stocks mentioned: NSRGY
PRNewsWire - 6 months ago

SAN DIEGO, Aug. 31, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Aimmune Therapeutics, Inc.

CNBC International TV - 6 months ago

Food allergies an immense opportunity, Nestle Health Science chief says

Nestlé Health Science CEO Greg Behar discusses the company's acquisition of food allergy biopharma company Aimmune Therapeutics and the opportunity in the food allergy space.

Other stocks mentioned: NSRGY
CNBC - 6 months ago

Nestle plans to pay $2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics, as the Swiss company expands its fast-growing health science business.

Other stocks mentioned: NSRGY
Benzinga - 6 months ago

Nestle S.A. (OTC: NSRGY) subsidiary Nestle Health Sciences (NHSc) is aquiring biopharma company Aimmune Therapeutics, Inc.

Other stocks mentioned: NSRGY
Reuters - 6 months ago

Nestle said on Thursday it was offering $34.50 per share for the remaining 74.4% in peanut allergy treatment maker Aimmune Therapeutics it does not already own, adding a potential blockbuster ...

Other stocks mentioned: NSRGY
Business Wire - 6 months ago

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics Inc.

Other stocks mentioned: NSRGY
GlobeNewsWire - 6 months ago

This press release is also available in Français (pdf) and Deutsch (pdf)

Other stocks mentioned: NSRGY
The Motley Fool - 6 months ago

Thanks to bad news for its competitor, this company behind the first FDA-approved peanut allergy treatment could be ripe for a rebound.

Business Wire - 6 months ago

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

The Motley Fool - 6 months ago

Is this battered biotech stock now a good deal for investors?

Benzinga - 6 months ago

Aimmune Therapeutics Inc (NASDAQ: AIMT) shares, which recovered Monday following an earnings-induced sell-off Friday, are adding to the gains.

Seeking Alpha - 7 months ago

Aimmune Therapeutics, Inc. (AIMT) CEO Jayson Dallas on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

Aimmune Therapeutics (AIMT) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the ...

Business Wire - 7 months ago

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights

Business Wire - 7 months ago

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights

Business Wire - 7 months ago

BRISBANE, Calif.--(BUSINESS WIRE)--Full Results of Aimmune’s Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA® Published in The Lancet Child & Adolescent Health

The Motley Fool - 7 months ago

These under-the-radar names pack some huge growth potential.

Other stocks mentioned: FOUR, CRLBF
InvestorPlace - 8 months ago

Aimmune Therapeutics may be struggling now in the Best Stocks contest, but the future is still bright for AIMT stock thanks to Palforzia. The post Best Stocks for 2020: Expect Aimmune Stock to...

The Motley Fool - 8 months ago

Armed with the recent approval of Palforzia, the first FDA-approved treatment for peanut allergy, could Aimmune Therapeutics turn things around?

Seeking Alpha - 9 months ago

Aimmune Shares Look Cheap On A Discounted Cash Flow Basis

About AIMT

Aimmune Therapeutics, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and oth... [Read more...]

Industry
Biotechnology
IPO Date
Aug 6, 2015
CEO
Jayson Donald Alexander Dallas
Employees
339
Stock Exchange
NASDAQ
Ticker Symbol
AIMT
Full Company Profile

Financial Performance

Financial Statements